Adaptive changes after human immunodeficiency virus type 1 transmission

AIDS Research and Human Retroviruses

Volumn 18, Issue 8, 2002, Pages 545-556

  Lawson, Victoria A ^a,b,c   Oelrichs, Robert ^b,d,e   Guillon, Christophe ^f,g   Imrie, Allison A ^h,i   Cooper, David A ^h   Deacon, Nicholas J ^b,d   McPhee, Dale A ^a,b  

^a AIDS Cellular Biology Unit   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Macfarlane Burnet Institute for Medical Research and Public Health   (United States)

^e THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^f ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^g UNIVERSITÉ DE LYON   (France)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY;

ANTIBODY SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; MACROPHAGE; MOLECULAR CLONING; MONONUCLEAR CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEROCONVERSION; UNINDEXED SEQUENCE; VIREMIA; VIRUS INFECTIVITY; VIRUS ISOLATION; VIRUS TRANSMISSION;

ADAPTATION, PHYSIOLOGICAL; BASE SEQUENCE; DNA PRIMERS; GENES, ENV; GENETIC COMPLEMENTATION TEST; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; VIRULENCE; VIRUS REPLICATION;

EID: 0036266750     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922202753747897     Document Type: Article

References (64)

1. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection
2. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
3. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
4. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficency virus type 1 infection
5. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
6. + lymphocytes as prognostic markers of HIV-1 infection
7. Viral counts count in HIV infection
8. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission
9. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population
10. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection
11. + T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals
12. Transmission and pathogenesis of human immunodeficiency virus type 1
13. Genetypic and phenotypic characterization of HIV-1 patients with primary infection
14. HIV-1 genomic RNA diversification following sexual and parenteral virus transmission
15. Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection
16. Virologic characterization of primary human immunodeficiency virus type 1 infection in a health care worker following needlestick injury
17. Syncytium-inducing (SI) phenotype suppression at seroconversion after intramuscular inoculation of a non-syncytium-inducing/SI phenotypically mixed human immunodeficiency virus population
18. Anomalies in Nef expression within the central nervous system of HIV-1 positive individuals/AIDS patients with or without AIDS dementia complex
19. Granulocyte-macrophage colony-stimulating factor inhibits HIV-1 replication in monocyte-derived macrophages
20. Kinetics of HIV-1 replication and intracellular accumulation of particles in HTLV-I-transformed cells
21. Identification of a major co-receptor for primary isolates of HIV-1
22. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype
23. Isolation of HIV from Australian patients with AIDS, AIDS related conditions and healthy antibody positive individuals
24. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine
25. Rapid full-length genomic sequencing of two cytopathically heterogeneous Australian primary HIV-1 isolates
26. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI
27. Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions
28. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity
29. Quantitative assessment of HIV-1 DNA load by coamplification of HIV-1 gag and HLA-DQ-α genes
30. Simplified colorimetric analysis of polymerase chain reactions: Detection of HIV sequences in AIDS patients
31. DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells
32. Elimination of sequence ambiguities by a single-step modification of a solid-phase, single-stranded sequencing protocol
33. Unbiased estimation of the rates of synonymous and non-synonymous substitution
34. Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants
35. Impact of natural sequence variation in the V2 region of the envelope protein of human immunodeficiency virus type 1 on syncytium induction: A mutational analysis
36. Modulation of primary human immunodeficiency virus type 1 envelope glycoprotein-mediated entry by human antibodies
37. Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity
38. Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation
39. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120
40. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: Effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells
41. A simple phase-extraction assay for chloramphenicol acyltransferase activity
42. HIV-1 nomenclature proposal
43. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants
44. Evolution of sequence divergence among human immunodeficiency virus type 1 isolates derived from a blood donor and a recipient
45. Evolution of human immunodeficiency virus type 1 nucleotide sequence diversity among close contacts
46. Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: Rate of sequence change and low frequency of inactivating mutations
47. Host-specific driving force in human immunodeficiency virus type 1 evolution in vivo
48. Evolutionary mechanisms and population dynamics of the third variable envelope region of HIV within single hosts
49. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection
50. Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period
51. Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays
52. Causes of HIV diversity
53. Two receptors are required for antibody-dependent enhancement of human immunodeficiency virus type 1 infection: CD4 and Fc γ R
54. FcR-mediated enhancement of HIV-1 infection by antibody
55. Human immunodeficiency virus infection of monocytes: Relationship to Fc-γ receptors and antibody-dependent viral enhancement
56. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells
57. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection
58. Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41
59. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies
60. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1
61. Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread
62. Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: Definition of critical amino acids involved in cell tropism
63. Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction
64. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding